Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida Infections

Clicks: 1
ID: 301787
1997
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #413 of 530 articles by views in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 530 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The availability of reproducible antifungal susceptibility testing methods now permits analysis of data correlating susceptibility in vitro with outcome in vivo in order to define interpretive breakpoints. In this paper, we have examined the conceptual framework underlying interpretation of antimicrobial susceptibility testing results and then used these ideas to drive analysis of data packages developed by the respective manufacturers that correlate fluconazole and itraconazole MICs with outcome of candidal infections. Tentative fluconazole interpretive breakpoints for MICs determined by the National Committee for Clinical Laboratory Standards' M27-T broth macrodiltition methodology are proposed: isolates for which MICs are ⩽8 μg/mL are susceptible to fluconazole, whereas those for which MICs are ⩾64 μg/mL appear resistant. Isolates for which the MIC of fluconazole is 16–32 μg/mL are considered susceptible dependent upon dose (S-DD), on the basis of data indicating clinical response when > 100 mg of fluconazole per day is given. These breakpoints do not, however, apply to Candida krusei, as it is considered inherently resistant to fluconazole. Tentative interpretive MIC breakpoints for itraconazole apply only to mucosal candidal infections and are as follows: susceptible, ⩽0.125 μg/mL; S-DD, 0.25–0.5 μg/mL; and resistant, ⩾ 1.0 μg/mL. These tentative breakpoints are now open for public commentary.
Reference Key
openalex_W2134458167 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors John Rex, Michael A. Pfaller, J N Galgiani, Marilyn S. Bartlett, Ana Espinel‐Ingroff, Mahmoud A. Ghannoum, M. Lancaster, Frank C. Odds, Michael G. Rinaldi, Thomas J. Walsh, A L Barry
Journal Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Year 1997
DOI
10.1093/clinids/24.2.235
URL
https://academic.oup.com/cid/article-pdf/24/2/235/1173093/24-2-235.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.